Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

GenVec in-licenses rights to TNF-alpha for gene therapy applications

May 5, 1998

Phase I trial results presented for the antifolate LY-231514

May 5, 1998

Natural antitumor substances with broad-spectrum activity isolated by Banyu scientists

May 5, 1998

Antitumor agents of microbial origin discovered by Nippon Kayaku

May 5, 1998

Zeneca seeks new labeling for breast cancer therapy

May 5, 1998

FDA grants accelerated approval for Xeloda

May 4, 1998

Targeted cytotoxic therapy cures breast cancer in mice at nontoxic doses

May 1, 1998

Cancer drug discovery alliance formed

April 30, 1998

KW-2170: in vitro and in vivo antitumor activity of a new pyrazoloacridone

April 30, 1998

New polythiophene antitumor agents for treating slow-growing tumors

April 29, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...